VivoSeq
Respiratory

Moderate to Severe COPD

0

Pipeline Programs↗

2

Active Trials↗

10

Companies Involved↗

Moderate to Severe COPD is an early-stage landscape with 0 programs across 10 companies. The most active players are Pearl Therapeutics, Inc., Novartis, Aer Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pearl Therapeutics, Inc.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalA

Aer Therapeutics

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalChiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

0 programs

PreclinicalG

Ganzhou Hemay Pharmaceutical Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed16 · 80%
Not yet recruiting2 · 10%
Terminated2 · 10%

Clinical Trials

Trial Activity

20 trials

A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD
Not yet recruiting·AAer Therapeutics·Phase 2·NCT06731959·100 enrolled
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
Not yet recruiting·GGanzhou Hemay Pharmaceutical Co., Ltd·Phase 2·NCT07314242·120 enrolled
Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD
Completed·Novartis logoNovartis·Phase 4·NCT01959516·124 enrolled
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT05492877·381 enrolled
Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD
Completed·PPearl Therapeutics, Inc.·Phase 2·NCT03256552·66 enrolled
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
Completed·Novartis logoNovartis·Phase 4·NCT02371629·776 enrolled
Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD
Completed·PPearl Therapeutics, Inc.·Phase 2·NCT02109406·31 enrolled
A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
Completed·PPearl Therapeutics, Inc.·Phase 3·NCT02643082·20 enrolled
Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD
Completed·Chiesi Farmaceutici S.p.A. logoChiesi Farmaceutici S.p.A.·Phase 2·NCT01584505·191 enrolled
Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD
Completed·NNeutec Ar-Ge San ve Tic A.Ş·Phase 4·NCT02541006·58 enrolled
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
Completed·Novartis logoNovartis·Phase 4·NCT02603393·1,053 enrolled
Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD
Completed·PPulmagen Therapeutics·Phase 2·NCT00634413·91 enrolled
PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
Completed·PPearl Therapeutics, Inc.·Phase 2·NCT01566773·140 enrolled
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
Completed·SSunovion Respiratory Development Inc.·Phase 2·NCT02038829·96 enrolled
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Completed·Sanofi logoSanofi·Phase 3·NCT04456673·935 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)